Total Payments
$7,047
2024 Payments
$3,185
Companies
43
Transactions
291
Medicare Patients
1,219
Medicare Billing
$105,752
Payment Breakdown by Category
Food & Beverage$5,230 (74.2%)
Education$1,020 (14.5%)
Other$797.60 (11.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,230 | 271 | 74.2% |
| Education | $1,020 | 12 | 14.5% |
| Long term medical supply or device loan | $797.60 | 8 | 11.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,438 | 46 | $0 (2024) |
| Astellas Pharma US Inc | $718.60 | 30 | $0 (2024) |
| Janssen Biotech, Inc. | $587.98 | 23 | $0 (2024) |
| PFIZER INC. | $462.96 | 18 | $0 (2024) |
| Eisai Inc. | $433.50 | 7 | $0 (2024) |
| SEAGEN INC. | $428.40 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $387.86 | 24 | $0 (2024) |
| Amgen Inc. | $227.55 | 12 | $0 (2023) |
| Celgene Corporation | $207.37 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $201.09 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,185 | 112 | Novartis Pharmaceuticals Corporation ($987.36) |
| 2023 | $2,239 | 107 | E.R. Squibb & Sons, L.L.C. ($322.79) |
| 2022 | $844.07 | 35 | Seagen Inc. ($178.97) |
| 2021 | $779.48 | 37 | Astellas Pharma US Inc ($233.63) |
All Payment Transactions
291 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 12/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.56 | General |
| 11/25/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $26.41 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: Oncology | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.49 | General |
| 11/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SEAGEN INC. | — | Education | In-kind items and services | $99.99 | General |
| 11/04/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Oncology | ||||||
| 11/04/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.22 | General |
| Category: Oncology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: HORMONE THERAPY | ||||||
| 10/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $2.75 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 332 | 756 | $127,069 | $38,572 |
| 2022 | 7 | 413 | 673 | $104,317 | $31,016 |
| 2021 | 6 | 404 | 790 | $105,247 | $32,293 |
| 2020 | 2 | 70 | 82 | $12,846 | $3,872 |
Total Patients
1,219
Total Services
2,301
Medicare Billing
$105,752
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 434 | $98,518 | $30,033 | 30.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 32 | $7,424 | $2,364 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $8,700 | $2,250 | 25.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 111 | 241 | $5,061 | $2,008 | 39.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 24 | $7,366 | $1,917 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 176 | 327 | $74,229 | $23,352 | 31.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $13,572 | $3,803 | 28.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 25 | $5,800 | $1,640 | 28.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 17 | $5,117 | $1,474 | 28.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 134 | 199 | $4,179 | $589.80 | 14.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 15 | $756.75 | $101.16 | 13.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 19 | 51 | $663.00 | $56.07 | 8.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 161 | 328 | $74,456 | $25,392 | 34.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 48 | 48 | $16,704 | $4,284 | 25.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 16 | $3,712 | $1,074 | 28.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 27 | 97 | $4,894 | $798.98 | 16.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 125 | 196 | $4,116 | $588.00 | 14.3% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 28 | 105 | $1,365 | $155.41 | 11.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 45 | 54 | $12,258 | $3,788 | 30.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 25 | 28 | $588.00 | $84.00 | 14.3% |
About Ashley Henegar
Ashley Henegar is a Medical healthcare provider based in Bluefield, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2012. The National Provider Identifier (NPI) number assigned to this provider is 1659623817.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ashley Henegar has received a total of $7,047 in payments from pharmaceutical and medical device companies, with $3,185 received in 2024. These payments were reported across 291 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($5,230).
As a Medicare-enrolled provider, Henegar has provided services to 1,219 Medicare beneficiaries, totaling 2,301 services with total Medicare billing of $105,752. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical
- Location Bluefield, WV
- Active Since 10/11/2012
- Last Updated 10/11/2012
- Taxonomy Code 363AM0700X
- Entity Type Individual
- NPI Number 1659623817
Products in Payments
- KISQALI (Drug) $1,141
- Lenvima (Drug) $433.50
- REBLOZYL (Biological) $298.96
- IMBRUVICA (Drug) $234.09
- XTANDI (Drug) $230.52
- ERLEADA (Drug) $222.58
- OPDIVO (Biological) $219.87
- KEYTRUDA (Biological) $180.86
- Xospata (Drug) $167.08
- LIBTAYO (Biological) $154.18
- TAGRISSO (Drug) $118.27
- VERZENIO (Drug) $117.51
- BESREMI (Drug) $109.91
- Onivyde (Drug) $101.64
- DARZALEX (Biological) $99.00
- IBRANCE (Drug) $91.93
- Tivdak (Drug) $79.72
- LUMAKRAS (Drug) $78.42
- Kyprolis (Drug) $75.42
- ORGOVYX (Drug) $70.77
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.